Analyst Ratings for Regeneron Pharmaceuticals Inc. (REGN)

Updated: 2017-07-28

Analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have given it a consensus rating of Overweight. A consensus rating of Overweight was previously issued for REGN last month.

Of the 24 analysts covering the stock, 10 gave it a buy rating, 1 issued an overweight rating, 13 gave a hold rating, 0 gave an underweight rating, and 0 gave a sell rating. Compared to three months ago, there has been an decrease of 3 in the number of analysts with a positive outlook on the stock. Meanwhile, the number of analysts pessimistic about the company has increased by 0.

Many analysts weighed in on price targets for REGN. The most optimistic analyst gave a price target of 593, implying potential capital gains of 16.64 percent. The minimum price target given was 327, implying a possible loss of -35.68 percent. It is advisable to not rely only on price targets or ratings, as these can be biased for some stocks.

In the last 30 days, analysts have changed their quarterly earnings estimates upwards by an average of 0.48 percent. The average change in earnings estimates over the last 90 days is -0.14 percent. Meanwhile, fiscal year estimates have been revised upwards by 0.39 percent, compared to last month. If we look at the last 90 days instead, we find a net average change of 0.77 percent in FY estimates.

People are often interested in whether analysts were united in the direction of their revisions. 1 analysts have revised their quarterly estimates upwards in the past 30 days, which can be compared to the 0 analysts that decreased their estimates. Also over the last month, 1 analysts increased their estimates for the FY earnings, while 0 analysts made negative revisions to their fiscal year's estimates.

REGN has an estimated earnings growth rate of 24.83 percent as forecasted by analysts. It's possible to gain additional insight about growth valuation of a company by looking at the PEG ratio. A lower PEG ratio is favorable, because that is often interpreted as the company being fairly priced relative to its growth rate. People often look for the PEG ratio to be under 1, but many choose to perform ratio comparisons with other companies in the industry. The PEG ratio of REGN is 2.46.

REGN has traded between a high of 543.55 and a low of 325.35 over the past year. Currently the stock is 56.27 percent higher than its low, and 6.46 percent below the high. REGN has a P/E ratio of 61.18. Investors typically compare the P/E ratio to a company's peers in the industry. The REGN value stock report compares REGN to some of its peers using value stock charts. The market cap of REGN is $54.81 billion. REGN's next earnings release will be on 0000-00-00, which is days away.